NCCN Guidelines Update Recommends Ropeginterferon Alfa-2b for Polycythemia Vera
Ropeginterferon alfa-2b was moved to preferred status for patients with high- and low-risk polycythemia vera in a recent update to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
Emerging Therapies for Patients with PV
In his final thoughts, Dr Gerds discusses emerging therapies for the treatment of PV.
Understanding and Treating Uncontrolled PV
Uncontrolled PV is highlighted by a key opinion leader.
2 Clarke Drive Cranbury, NJ 08512